GREGoRi Innovation Projects (U01 Clinical Trial Optional)
The Genomics Research to Elucidate the Genetics of Rare Diseases:innovation (GREGoRi) initiative seeks to accelerate a paradigm shift in rare disease diagnosis by reimagining the tools, molecular technologies and analytical approaches used to identify the causal gene(s) and/or variant(s) underlying rare genetic disorders. This Notice of Funding Opportunity is intended to stimulate the development and testing of highly innovative experimental or computational approaches for rare disease diagnosis, that have the potential to make transformative improvements to the current state of the art.
RFA-HG-27-013
Award Ceiling
$500K
Closes
Oct 30, 2026
3d left
HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required)
<p>The NIH Helping to End Addiction Long-term<span style="background-color:rgb(198,177,222)!important;"><s><sup>®</sup></s></span><sup> </sup>(HEAL) Initiative is releasing this Notice of Funding Opportunity (NOFO) to support a phased mechanistic clinical research program focusing on understudied biological mechanisms that drive joint pain. The phased projects supported by this program (of up to five years total in duration) will first identify and validate multi-tissue mechanisms underlying joint pain, then test non-pharmacologic or multimodal interventions that directly target these mechanisms. The initiative responds to priorities identified in the 2023 HEAL Whole Joint Pain Workshop and supports the broader goals of the NIH HEAL Initiative and the Make America Healthy Again vision by advancing safe, non-addictive, and prevention-oriented approaches to chronic pain.</p>
PAR-27-045
Award Ceiling
—
Closes
Oct 30, 2026
3d left
GREGoRi Technology Integration Center (U01, Clinical Trials Optional)
The Genomics Research to Elucidate the Genetics of Rare Diseases:innovation (GREGoRi) initiative seeks to accelerate a paradigm shift in rare disease diagnosis by reimagining the tools, molecular technologies and analytical approaches used to identify the causal gene(s) and/or variant(s) underlying rare genetic disorders. The purpose of this Notice of Funding Opportunity is to establish the GREGoRi Technology Integration Center, which will enable the development of standards and best practices for applying new and emerging molecular methods in rare disease diagnosis. A major deliverable of the Center will be a multidimensional dataset that can be used for the development and benchmarking of novel tools and strategies that facilitate rare disease diagnosis.
RFA-HG-27-012
Award Ceiling
$2.3M
Closes
Oct 30, 2026
3d left
GREGoRi Data Coordination and Outreach Center (U01, Clinical Trials Not Allowed)
The Genomics Research to Elucidate the Genetics of Rare Diseases:innovation (GREGoRi) initiative seeks to accelerate a paradigm shift in rare disease diagnosis by reimagining the tools, molecular technologies and analytical approaches used to identify the causal gene(s) and/or variant(s) underlying rare genetic disorders. The purpose of this Notice of Funding Opportunity is to establish the GREGoRi Data Coordination and Outreach Center. The Data Coordination and Outreach Center will act as the central point of coordination for the GREGoRi Research Program, and will be responsible for ensuring that the protocols, data, metadata, computational tools and other resources developed as part of GREGoRi are made available to the broader research community.
RFA-HG-27-011
Award Ceiling
$1.3M
Closes
Oct 30, 2026
3d left
Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
This Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required) PAR, a re-issue of PAR-24-035, was re-issued as a result of the Simplifying Review of Research Project Grant Applications [link: https://grants.nih.gov/policy-and-compliance/policy-topics/peer-review/simplifying-review]. The Simplify Review changes in Section V are the only changes that have been made. All other aspects of this funding opportunity remain the same.
PAR-24-279
Award Ceiling
—
Closes
Nov 2, 2026
6d left
National Indian Health Outreach and Education
The purpose of this NOFO is to further the IHS mission and goals related to providing quality health care to the AI/AN community through outreach and education. Our focus is on promoting awareness, visibility, training, technical assistance, and education in the following components:Health education and outreach.Rural Health Transformation review and outreach and education on the Indian Health Care Improvement Act.Substance abuse and suicide prevention.Domestic violence prevention.Special diabetes program for American Indians.Tribal budget formulation activities.Tribal youth health advisory activities.
HHS-2026-IHS-NIHOE-0001
Award Ceiling
$1.1M
Closes
Nov 2, 2026
6d left
Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
This Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed) PAR, was re-issued as a result of the Simplifying Review of Research Project Grant Applications [link: https://grants.nih.gov/policy-and-compliance/policy-topics/peer-review/simplifying-review]. The Simplified Review changes in Section V are the only changes that have been made. All other aspects of this funding opportunity remain the same.
PAR-24-280
Award Ceiling
—
Closes
Nov 2, 2026
6d left
Emerging Infections Network - Research for Preventing, Detecting, and Managing Travel-associated Infectious Diseases
The focus of this notice of funding opportunity (NOFO) is to produce insights into disease detection and prevention strategies, burden, severity, diagnostics, treatment, and outcomes of infectious diseases in international travelers. Timely surveillance and sentinel detection are essential for collecting actionable data. The research should:Address public health questions that improve the speed of outbreak detection.Help develop guidelines and recommendations to improve patient care.Enhance understanding of the natural history of disease.Optimize genomic surveillance as well as diagnostic and treatment strategies.Advance the global health security of the United States.This NOFO will have two components:Component A – Clinic-based sentinel network.Component B – Sentinel detection in international transportation hubs.You may apply for Component A, B, or both. If your application for both Component A and B is ranked top, Component B will be awarded.
RFA-CK-26-035
Award Ceiling
$6.0M
Closes
Nov 5, 2026
9d left
US Travelers Health Research, Surveillance, Communication, and Outreach Network
The NOFO supports CDC"s efforts to protect U.S. residents traveling internationally. The goal is to help U.S. travelers with pre-travel preparation, access to timely health information while traveling, and timely research on health conditions.The project will:Improve access to high quality travel preparation information for both healthcare providers and travelers.Collect health information before, during, and after travel through innovative electronic medical record (EMR), web, and mobile phone applications.Build on this platform to conduct timely research on emerging health threats.This NOFO will also increase the awareness of travel medicine among primary care providers and provide them with appropriate tools in advising international travelers with up-to-date recommendations.
RFA-CK-26-036
Award Ceiling
$1.0M
Closes
Nov 5, 2026
9d left
Limited Competition for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required)
This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding. This NOFO requests limited competition applications for a 3-year extension of the COPE-AKI clinical trial consortium, which includes three clinical centers (CCs) and one scientific and data research center (SDRC), to fully meet the enrollment targets, complete participant follow-up, and provide resources for data analysis and dissemination of study findings. There is currently no standard of care for patients after hospitalization with acute kidney injury (AKI). Successful completion of the COPE-AKI study will provide key insights that are expected to directly inform improved clinical management strategies and the development of standard of care for Stage 2 and 3 AKI survivors.
RFA-DK-27-125
Award Ceiling
$1.9M
Closes
Nov 6, 2026
10d left
Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
This is a Notice of Funding Opportunity (NOFO) for a Single Source that will invite an application from the eligible organization to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, applications will be peer-reviewed, and only meritorious applications will be considered for funding. Through this NOFO, the National institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites an application to continue to follow the Epidemiology of Diabetes Interventions and Complications (EDIC) cohort through a collaborative cooperative agreement that addresses specific knowledge gaps in the development and progression of type 1 diabetes complications. Applications should include hypothesis-based research, support for cohort infrastructure and/or maintenance, continued follow-up, and supporting collaborative research to utilize the EDIC cohort as well as its data set and biologic/genetic samples.
RFA-DK-27-112
Award Ceiling
$6.3M
Closes
Nov 9, 2026
13d left
Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
Applications for a 3-year extension/renewal of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) clinical trial consortium are requested to fully meet the enrollment targets, complete participant follow-up, and finalize data analysis and dissemination of study findings. This Notice of Funding Opportunity (NOFO) invites a Single Source application for the eligible organization, the Scientific and Data Research Center (SDRC) already involved in the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Consortium. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered.There is currently no standard of care for patients after hospitalization with acute kidney injury (AKI). Successful completion of the COPE-AKI study will provide key insights that are expected to directly inform improved clinical management strategies and the development of standard of care for Stage 2 and 3 AKI survivors.
RFA-DK-27-139
Award Ceiling
$1.8M
Closes
Nov 9, 2026
13d left
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products as described in section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb). These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS.
RFA-NS-26-001
Award Ceiling
$40.0M
Closes
Nov 10, 2026
14d left
Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies offering new capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens for basic, clinical, or epidemiological cancer research. The NOFO solicits R61 applications for early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. Technologies proposed for development may have potential for widespread applicability but must be focused for this program on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
RFA-CA-27-001
Award Ceiling
$150K
Closes
Nov 10, 2026
14d left
Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
This Notice of Funding Opportunity (NOFO) invites applications proposing a Data Coordinating Center that integrates and disseminates multiscale mouse brain datasets for the aging and Alzheimer's disease (AD) research community. The Data Coordinating Center will establish the Aging and AD Mouse Brain Atlas (AD-MBA), which will serve as a central, unified research resource for multi-omic and connectomic mouse brain datasets emerging from the NIA AD Multimodal Atlas Projects (AD-MAPs). The Data Coordinating Center will (1) leverage the NIA-supported AD Knowledge Portal data infrastructure to facilitate hosting, deposition, and dissemination of multimodal datasets generated by the AD-MAPs program, (2) facilitate collaborative analyses among the data-contributing teams, (3) develop/optimize and incorporate tools for multiscale integration of multi-omics and connectomics datasets, and (4) create a broadly accessible web-based interface for the visualization and dissemination of integrated multiscale data.
RFA-AG-27-010
Award Ceiling
$2.5M
Closes
Nov 10, 2026
14d left
Pilot Projects to Enhance the Human Virome Program (R03 Clinical Trials Not Allowed)
<p>The Common Fund Human Virome Program (HVP) aims to extensively and comprehensively characterize the "healthy" human virome (the collection of viruses that normally reside inside the human body without evidence of disease) and create tools, models, and methods that will enable an in-depth study of its variation and composition in relation to host factors and its influence on health and disease.</p><p>The purpose of this NOFO is to support small pilot projects that extend the goals of the HVP, including further validating, improving, and complementing existing and newly developed tools from the HVP program by leveraging human specimens collected from the cohorts under the program; samples from animals to promote the refinement, utilization, and translation of these tools to better serve the goals of the HVP program; expanding existing cohorts and/or biospecimen sampling sites for virome characterization; developing tools, assays, and methods to study the human virome; and defining functional interactions between the human virome and host. These pilot projects will expand the HVP consortium, and collaboration across the HVP is expected. Applicants outside the current HVP are encouraged to apply and pilot projects should not overlap with existing HVP efforts (visit the <a href="https://grants.nih.gov/funding/find-a-fit-for-your-research/nih-institutes-centers-offices/osc">Common Fund website</a> for a list of funded research).</p>
RFA-RM-27-024
Award Ceiling
$100K
Closes
Nov 10, 2026
14d left
Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites grant applications proposing exploratory research projects focused on further development and technical validation of emerging technologies offering novel capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens used for basic, clinical, or epidemiological cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous technical validation to encourage adoption by the research community. Well-suited applications must propose the development of technologies that offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, epidemiology. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
RFA-CA-27-002
Award Ceiling
$300K
Closes
Nov 10, 2026
14d left
Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)
The purpose of this notice of funding opportunity (NOFO) is to support a Clinical Research Network (CRN) on Antimicrobial Resistance (AMR). The program aims to design, implement, and manage clinical research that addresses pivotal clinical questions related to AMR through a coordinated and integrated CRN. The CRN will comprise four centers: the Scientific Leadership Center (SLC), the Clinical Operations Center (COC), the Laboratory Center (LC), and the Statistics and Data Coordination Center (SDCC).
RFA-AI-27-005
Award Ceiling
$18.0M
Closes
Nov 10, 2026
14d left
Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
The purpose of this notice of funding opportunity (NOFO) is to solicit applications for an Infectious Diseases Clinical Trials Network (IDCTN). The IDCTN, comprised of the Clinical Trial Evaluation Units (CTEUs) and a Network Coordination Center (NCC), supports the evaluation of interventions for emerging and chronic infections. The CTEUs design and implement clinical trials and studies, while the NCC provides the administrative and operational framework for a collaborative, integrated network and engages with experts in the field to solicit and generate clinical trial concepts. The NCC and CTEUs will collaboratively create opportunities to advance investigators early in their careers and those new to the field.
RFA-AI-27-002
Award Ceiling
$10.0M
Closes
Nov 10, 2026
14d left
Limited Competition: NIH Research Evaluation and Commercialization Hubs (REACH) (SB0 Clinical Trial Optional)
This Notice of Funding Opportunity (NOFO) announces the renewal of the NIH Research Evaluation and Commercialization Hub (REACH) program, established to facilitate and accelerate the translation of academic biomedical discoveries into products that improve patient care and public health. Through this program, NIH will provide the qualifying institutions with the funds to seed the creation of academic entrepreneurship Hubs. Hubs will be responsible for providing innovators with both the initial investment and resources to support the proof-of-concept work and the mentorship in product development and commercialization needed to develop high priority technologies within the NIH's mission. Funded Hubs are intended to work as a consortium to enable: (1) the infrastructure for identifying the most promising technologies, (2) funding for product definition studies (e.g. feasibility studies, prototype development, proof-of-concept studies) provided to individual researchers, (3) access to resources and expertise in areas required for early stage technology development (including scientific, regulatory, reimbursement, business, legal, and project management), and (4) skills development and hands-on experience in entrepreneurship. Establishing public-private partnerships and providing additional non-federal funds will be critical for success. This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite applications from eligible organizations to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.
RFA-OD-27-009
Award Ceiling
$5.0M
Closes
Nov 10, 2026
14d left